Elixia: A Revolution in Clinical Research
American Clinical Research Services, now known as Elixia, has rebranded to reflect its expanded clinical research and patient recruitment...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Innovation Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials protocol amendments Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
American Clinical Research Services, now known as Elixia, has rebranded to reflect its expanded clinical research and patient recruitment...
SamanTree Medical, a leading medical technology company specializing in surgical advancements, has secured $14 million in a Series B...
Oncodesign Precision Medicine (OPM) has announced positive results from a Phase 1 trial evaluating OPM-101, a selective small molecule...
Introduction The COVID-19 pandemic has significantly disrupted traditional clinical research practices, accelerating the shift towards Decentralized Clinical Trials (DCTs)....
At the 25th International AIDS Conference in Munich, ViiV Healthcare will unveil significant findings from their portfolio of HIV...
Amylyx Pharmaceuticals has acquired avexitide, an investigational therapy for hyperinsulinemic hypoglycemia, from Eiger BioPharmaceuticals. Avexitide, a novel GLP-1 receptor...
The National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) as an additional treatment option for...
Recent research published in Science Translational Medicine offers promising advancements in developing regenerative therapies for diabetes. A team of...
Pfizer has selected a once-daily formulation of danuglipron, an oral GLP-1 receptor agonist, based on encouraging results from an...
We are excited to bring you an insightful conversation with Robert Towarnicki, Co-Founder and CEO of Sirpant Immunotherapeutics. In...